Results 161 to 170 of about 7,331 (198)
Post-COVID Postural Orthostatic Tachycardia Syndrome and Inappropriate Sinus Tachycardia: Prevalence, Overlap, and Clinical Characteristics. [PDF]
JACC AdvJuszczyk M +6 more
europepmc +1 more source
Pharmacological and non-pharmacological management of long COVID. [PDF]
Virol JKhalid K, Abdullah ADI, Lim HX, Ali RAR.
europepmc +1 more source
First eco-toxicological evidence of ivabradine effect on the marine bacterium Vibrio fischeri: A chiral view [PDF]
Science of the Total Environment, 2022 Ivabradine (S-ivabradine) is a contemporary antihypertensive drug designed and commercialized for cardiovascular diseases treatment over the world. In this work the enantiomer-specific stability and acute toxicity of ivabradine to the marine bacterium ...
Georgiana Amariei +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2022
Abstract The cells of the sinoatrial (SA) node generate a cyclical change in their resting membrane potential that drives them towards the threshold that triggers an action potential. The spontaneous depolarization current is a combined Na+/K+ inward current, termed the Ifunny current (I(f)).
openaire +2 more sources
Abstract The cells of the sinoatrial (SA) node generate a cyclical change in their resting membrane potential that drives them towards the threshold that triggers an action potential. The spontaneous depolarization current is a combined Na+/K+ inward current, termed the Ifunny current (I(f)).
openaire +2 more sources
2016
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary ...
openaire +2 more sources
Ivabradine is a blocker of the funny current channels in the sinoatrial node cells. This results in pure heart rate reduction when elevated without direct effect on contractility or on the vessels. It was tested in a large outcome clinical trial in stable chronic heart failure (CHF) with low ejection fraction, in sinus rhythm, on a contemporary ...
openaire +2 more sources
Ivabradine: A Current Overview
Current Clinical Pharmacology, 2016Ivabradine, acting on the funny channel (If) in the sino-atrial node, reduces myocardial oxygen demand without inducing hypotension. It was developed as a specific bradycardic agent in the 1980s, avoiding the adverse effects of more traditional antianginal agents (beta-blockers and calcium channel antagonists).
Kaushik, Guha +3 more
openaire +2 more sources
Ivabradine: Cardiovascular Effects
Recent Patents on Cardiovascular Drug Discovery, 2009Ivabradine (a compound of the benzocyclobutane) is a highly selective I(f) current inhibitor acting directly on the sino-atrial node, induces a rapid, sustained and dose-dependent reduction of heart rate at rest and during exercise without a significant effect on atrio-ventricular conduction, left ventricular contraction/relaxation or vascular tissues.
Andrea, Rognoni +3 more
openaire +2 more sources
▼Ivabradine for stable angina?
Drug and Therapeutics Bulletin, 2008Up to 1 in 25 people in Europe and the USA have stable angina, with symptoms that may limit function and quality of life.1,2 Beta-blockers are usually used in initial symptomatic treatment, but may cause unwanted effects.3–6 They are also contraindicated in some patients (e.g.
openaire +2 more sources